Home \ Browse Journal \ 2025 \ 2025 Volume 8 Issues 1–3 \ New Pyridine-Containing Azacrown Chelators PATPy and PAPPy for Pb2+ Ion

2025 Volume 8 Issues 1–3

инэос-open
Open Access
cc-by-nc

INEOS OPEN, 2025, 8 (1–3), 16–17 

Journal of Nesmeyanov Institute of Organoelement Compounds
of the Russian Academy of Sciences

Download PDF
Electronic supplementary information
DOI: 10.32931/io2504a

issue_cover_8_1-3.png       

New Pyridine-Containing Azacrown Chelators
PATPy and PAPPy for
Pb2+ Ion

O. V. Tarasenko,*a,b A. A. Shchukina,a A. D. Zubenko,a and Yu. V. Fedorova

a Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, ul. Vavilova 28, str. 1, Moscow, 119334 Russia
b Mendeleev University of Chemical Technology of Russia, Miusskaya pl. 9, Moscow, 125047 Russia
 

Corresponding author: O. V. Tarasenko, e-mail: taraseoksana@yandex.ru
Received 9 September 2024; accepted 15 October 2024

Abstract

N N N N N N N N N Pb 2+ N N N N N N N N N N N Pb 2+ PAPPy + Pb 2+ PATPy + Pb 2+ rigid asymmetric complex several different conformers

New macrocyclic chelators with four and five pendant pyridine groups, PATPy and PAPPy, are synthesized and characterized. Their ability to coordinate with Pb2+ ion was studied using NMR spectroscopy and mass spectrometry. It was shown that both chelators form Pb2+ complexes of M:L = 1:1 composition. The NMR spectroscopic studies revealed the formation of a rigid asymmetric complex Pb·PATPy and rapid dynamic transitions between several different conformers of Pb·PAPPy in solution.

Key words: azacrown ether, chelator, ligand, metal complex, lead.

 

Introduction

In recent years, many investigations have been focused on finding the ligands capable of strong binding with Pb2+ ion [1–3]. This is not only due to its high toxicity, which requires the development of effective lead extracting agents [1], but also due to the radiochemical properties of some lead isotopes [2–7]. Two prominent radioisotopes of lead are 203Pb (t1/2 = 51.9 h) and 212Pb (t1/2 = 10.6 h) [2]. 203Pb has γ-emission at 279 keV which is ideal for single-photon emission computed tomography (SPECT) [3–5]. 212Pb decays via β− particle emission to form the α-emitting daughter radionuclide 212Bi (t1/2 = 60.6 min), which makes this isotope attractive for the therapy of oncological diseases [2–7].

According to Pearson's HSAB theory, lead(II) is considered to be a moderate Lewis acid. For the formation of stable complexes with this ion, a ligand should have pyridine and amide donor units, which are moderate bases [1, 8–10]. Macrocyclic chelators are more attractive than acyclic as they have a pre-organized cavity for binding metal cations, resulting in thermodynamically stable and kinetically inert complexes [9, 10]. In addition, incorporating rigid spacers such as a pyridine moiety into the ligand backbone may result in lower kinetic lability [10].

Herein, we report the synthesis of new macrocyclic ligands, PATPy and PAPPy, which are 15- and 18-membered pyridine-azacrown ethers with pyridyl chelating groups for binding Pb2+ ion. The complexing features of these ligands towards Pb2+ ion were studied by NMR spectroscopy and mass spectrometry.

Results and discussion

The synthesis of the target ligands is shown in Scheme 1. Bisamide macrocycles 1 and 2, synthesized according to the method reported by us earlier [11], were reduced to obtain pyridine-azacrown ethers 3 and 4. To identify the most optimal reducing agent, three different borane complexes were used: BH3∙THF, BH3∙DMS, and BH3∙pyridine (Table 1). The amount of the reducing agent was also varied to achieve a maximum conversion of the initial macrocycle. The conversions were determined by analyzing the 1H NMR spectra of the reaction mixtures. It was found that the most effective reducing agent for both of the macrocycles was BH3∙THF. However, compound 2 requires a larger excess of the borane complex (60 equiv.) than compound 1 (20 equiv.).

PATPy , n=1, 67% PAPPy , n=2, 63% N Cl + Cl - N N N N N N N N N N NH HN NH HN K 2 CO 3 , MeCN, D 3 , n=1, 81% 4 , n=2, 72% N NH HN O O NH HN 1 , n=1 2 , n=2 1) BH 3 THF, 0°C 2) HCl, D 3) KOH n n n .  

Scheme 1. Synthesis of ligands PATPy and PAPPy.

Table 1. Optimization of the reduction step using borane complexes

Macrocycle
Reducing agent
Excess (equiv.)
Conversion
1
BH3∙THF
20
1.0
BH3∙DMS
20
0.9
BH3∙pyridine
20
0.3
2
BH3∙THF
20
0.5
 
40
0.7
 
60
1.0
BH3∙DMS
20
0.4
 
40
0.9
BH3∙pyridine
20
0.2

The introduction of chelating groups was accomplished by the alkylation of azacrown ethers 3 and 4 with 2-(chloromethyl)pyridine in MeCN in the presence of a base (Scheme 1). The target ligands were isolated after purification by column chromatography in 67 and 63% yields, respectively.

The complexation of the resulting ligands with Pb2+ion was studied using ESI mass spectrometry and 1H NMR spectroscopy. The mass spectrometry method afforded the data on the composition of the resulting species, showing that both chelators form a single complex with Pb2+ ion in solution with an M:L ratio of 1:1 (Fig. 1).

io2504a_fig1

Figure 1. ESI MS of complexes Pb·PATPy and Pb·PAPPy.

The structural studies of the Pb2+ complexes with PATPy and PAPPy were performed using NMR spectroscopy (Fig. 2). The 1H NMR spectrum of complex Pb·PATPy was found to be significantly complicated compared to that of the free ligand. The presence of the well-resolved signals, their increased number and integral intensities indicated the formation of rigid asymmetric complex Pb·PATPy in solution. Of note is a singlet in the spectrum (highlighted in green) presumably assigned to one free pyridyl unit. In contrast to Pb·PATPy, the 1H NMR spectrum of complex Pb·PAPPy contains broadened signals in the regions of both aliphatic and aromatic proton signals, which can be explained by the rapid dynamic transformations between different conformers. This feature indicates a discrepancy between the ligand structure and metal ion, as well as the lability of the resulting complex.

io2504a_fig2

Figure 2. 1H NMR spectra of free ligands PATPy and PAPPy and their Pb2+ complexes in CD3CN.

Conclusions

Two novel chelators for Pb2+ ion were synthesized and fully characterized. Their metal ion chelation was studied using ESI mass spectrometry and NMR spectroscopy. It was shown that only PATPy forms a complex with Pb2+ ion featuring a rigid asymmetric structure, while complex Pb·PAPPy was found to be labile. Hence, further studies of PATPy as a chelating agent for Pb2+ ion seems to be very promising.

Acknowledgements

This work was supported by the Russian Science Foundation (project no. 23-13-00424). The NMR and ESI/MS studies were performed using the equipment of the Center for Molecular Composition Studies of INEOS RAS.

Electronic supplementary information

Electronic supplementary information (ESI) available online: the experimental section and NMR spectra of the compounds obtained. For ESI, see DOI: 10.32931/io2504a.

References

  1. F. Cuenot, M. Meyer, E. Espinosa, A. Bucaille, R. Burgat, R. Guilard, C. Marichal-Westrich, Eur. J. Inorg. Chem., 2008, 267–283. DOI: 10.1002/ejic.200700819
  2. A. Ingham, T. I. Kostelnik, B. L. McNeil, B. O. Patrick, N. Choudhary, M. Jaraquemada-Peláez, C. Orvig, Dalton Trans., 2021, 50, 11579–11595. DOI: 10.1039/d1dt01653a
  3. L. L. Chappell, E. Dadachova, D. E. Milenic, K. Garmestani, C. C. Wu, M. W. Brechbiel, Nucl. Med. Biol., 2000, 27, 93–100. DOI: 10.1016/s0969-8051(99)00086-4
  4. D. E. Milenic, M. Roselli, M. W. Brechbiel, C. G. Pippin, T. J. McMurray, J. A. Carrasquillo, D. Colcher, R. Lambrecht, O. A. Gansow, J. Schlom, Eur. J. Nucl. Med., 1998, 25, 471–480. DOI: 10.1007/s002590050246
  5. S. R. Banerjee, I. Minn, V. Kumar, A. Josefsson, A. Lisok, M. Brummet, J. Chen, A. P. Kiess, K. Baidoo, C. Brayton, R. C. Mease, M. Brechbiel, G. Sgouros, R. F. Hobbs, M. G. Pomper, J. Nucl. Med., 2020, 61, 80–88. DOI: 10.2967/jnumed.119.229393
  6. J. Li, T. Huang, J. Hua, Q. Wang, Y. Su, P. Chen, S. Bidlingmaier, A. Li, Z. Xie, A. P. Bidkar, S. Shen, W. Shi, Y. Seo, R. R. Flavell, D. Gioeli, R. Dreicer, H. Li, B. Liu, J. He, J. Exp. Clin. Cancer Res., 2023, 42, 61. DOI: 10.1186/s13046-023-02636-x
  7. B. Bartoś, K. Lyczko, A. Kasperek, S. Krajewski, A. Bilewicz, J. Radioanal. Nucl. Chem., 2013, 295, 205–209. DOI: 10.1007/s10967-012-2238-4
  8. M. Fernández-Fernández, R. Bastida, A. Macías, L. Valencia, P. Pérez-Lourido, Polyhedron, 2006, 25, 783–792. DOI: 10.1016/j.poly.2005.07.045
  9. B. L. McNeil, K. J. Kadassery, A. W. McDonagh, W. Zhou, P. Schaffer, J. J. Wilson, C. F. Ramogida, Inorg. Chem., 2022, 61, 9638–9649. DOI: 10.1021/acs.inorgchem.2c01114
  10. C. Harriswangler, B. L. McNeil, I. Brandariz-Lendoiro, F. Lucio-Martínez, L. Valencia, D. Esteban-Gómez, C. F. Ramogida, C. Platas-Iglesias, Inorg. Chem. Front., 2024, 11, 1070–1086. DOI: 10.1039/d3qi02354k
  11. Y. Fedorov, O. Fedorova, A. Peregudov, S. Kalmykov, B. Egorova, D. Arkhipov, A. Zubenko, M. Oshchepkov, J. Phys. Org. Chem., 2016, 29, 244–250. DOI: 10.1002/poc.3526